(RTTNews) - Aptinyx Inc. (APTX) said that a phase 2b study of NYX-2925 in Fibromyalgia did not achieve statistically significant separation from placebo on the study's primary endpoint, which assessed ...
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results